FIELD: chemistry.
SUBSTANCE: invention relates to immunology. Disclosed is an antibody which binds to B7-H3 and has activity in antibody-dependent cellular phagocytosis (ADCP) and antitumour activity in vivo. Polynucleotide, a vector, a host cell and a method of producing an antibody of the invention using same are also disclosed. In addition, pharmaceutical compositions and methods for treating a tumour are provided.
EFFECT: present invention can find further application in the treatment of various diseases.
40 cl, 67 dwg, 4 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
ANTIBODY-DRUG CONJUGATE | 2013 |
|
RU2664465C2 |
ANTIBODY-DRUG CONJUGATE | 2013 |
|
RU2776489C2 |
IMPROVED METHODS OF TREATING VASCULARISED MALIGNANT TUMORS | 2015 |
|
RU2692248C2 |
ANTIBODY AGAINST GPR20 AND ANTIBODY AGAINST GPR20-DRUG CONJUGATES | 2018 |
|
RU2772804C2 |
ANTI-ROBO4 ANTIBODY | 2013 |
|
RU2682451C2 |
ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
ANTI-GARP ANTIBODY | 2016 |
|
RU2769379C2 |
NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2590711C2 |
NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2644678C1 |
Authors
Dates
2018-09-26—Published
2012-04-24—Filed